Department of Gastroenterology and Hepatology, Ground Floor Alfred Centre, Alfred Health, 55 Commercial Road, Melbourne, VIC, 3004, Australia.
Central Clinical School, Monash University, Melbourne, Australia.
Hepatol Int. 2023 Oct;17(5):1082-1097. doi: 10.1007/s12072-023-10568-z. Epub 2023 Aug 9.
For the first time in nearly half a century, fatty liver disease has undergone a change in name and definition, from the exclusive term, non-alcoholic fatty liver disease (NAFLD), to the inclusion-based, metabolic-associated fatty liver disease (MAFLD). This has led investigators across the globe to evaluate the impact the nomenclature change has had on the epidemiology and natural history of the disease.
This systematic review provides a comprehensive overview on how the shift in name and diagnostic criteria has influenced point prevalence in different geographic regions, as well as morbidity and mortality risk, whilst highlighting gaps in the literature that need to be addressed.
MAFLD prevalence is higher than NAFLD prevalence, carries a higher risk of overall mortality, with greater granularity in risk-stratification amongst MAFLD subtypes.
近半个世纪以来,脂肪肝疾病的名称和定义首次发生变化,从专有的非酒精性脂肪性肝病 (NAFLD) 变为基于包含的代谢相关脂肪性肝病 (MAFLD)。这促使全球各地的研究人员评估命名变化对疾病的流行病学和自然史的影响。
本系统综述全面概述了名称和诊断标准的转变如何影响不同地理区域的时点患病率,以及发病率和死亡率风险,同时强调了文献中的空白需要解决。
MAFLD 的患病率高于 NAFLD,整体死亡率风险更高,MAFLD 亚型的风险分层更具粒度。